These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32671945)

  • 21. Functional dyspepsia: new insights into pathogenesis and therapy.
    Talley NJ
    Korean J Intern Med; 2016 May; 31(3):444-56. PubMed ID: 27048251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dysbiosis of the Duodenal Mucosal Microbiota Is Associated With Increased Small Intestinal Permeability in Chronic Liver Disease.
    Raj AS; Shanahan ER; Tran CD; Bhat P; Fletcher LM; Vesey DA; Morrison M; Holtmann G; Macdonald GA
    Clin Transl Gastroenterol; 2019 Aug; 10(8):e00068. PubMed ID: 31373933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concentration of Glial Cell Line-Derived Neurotrophic Factor Positively Correlates with Symptoms in Functional Dyspepsia.
    Tanaka F; Tominaga K; Fujikawa Y; Nagami Y; Kamata N; Yamagami H; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y; Arakawa T
    Dig Dis Sci; 2016 Dec; 61(12):3478-3485. PubMed ID: 27718082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proton pump inhibitors: effective first-line treatment for management of dyspepsia.
    Peura DA; Gudmundson J; Siepman N; Pilmer BL; Freston J
    Dig Dis Sci; 2007 Apr; 52(4):983-7. PubMed ID: 17342402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut microbiome dysbiosis and increased intestinal permeability in children with islet autoimmunity and type 1 diabetes: A prospective cohort study.
    Harbison JE; Roth-Schulze AJ; Giles LC; Tran CD; Ngui KM; Penno MA; Thomson RL; Wentworth JM; Colman PG; Craig ME; Morahan G; Papenfuss AT; Barry SC; Harrison LC; Couper JJ
    Pediatr Diabetes; 2019 Aug; 20(5):574-583. PubMed ID: 31081243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use.
    Naito Y; Kashiwagi K; Takagi T; Andoh A; Inoue R
    Digestion; 2018; 97(2):195-204. PubMed ID: 29316555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low yield of endoscopy in patients with persistent dyspepsia taking proton pump inhibitors.
    Smith T; Verzola E; Mertz H
    Gastrointest Endosc; 2003 Jul; 58(1):9-13. PubMed ID: 12838213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tangible pathologies in functional dyspepsia.
    Walker MM; Potter MD; Talley NJ
    Best Pract Res Clin Gastroenterol; 2019; 40-41():101650. PubMed ID: 31594648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Duodenal eosinophilia in functional dyspepsia in a Colombian sample: a case-control study].
    Lúquez Mindiola A; Otero Regino W; Gómez Zuleta M
    Rev Gastroenterol Peru; 2019; 39(1):21-26. PubMed ID: 31042233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies.
    Macke L; Schulz C; Koletzko L; Malfertheiner P
    Aliment Pharmacol Ther; 2020 Mar; 51(5):505-526. PubMed ID: 31990420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New horizon of the pathophysiology of functional dyspepsia].
    Futagami S; Yamawaki H; Hashimoto S; Iwakiri K
    Nihon Shokakibyo Gakkai Zasshi; 2016; 113(6):927-35. PubMed ID: 27264424
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pathophysiology and therapy of functional dyspepsia].
    Kaneko H; Konagaya T; Goto H
    Nihon Shokakibyo Gakkai Zasshi; 2009 Mar; 106(3):335-45. PubMed ID: 19262047
    [No Abstract]   [Full Text] [Related]  

  • 33. [Functional Dyspepsia].
    Oh JH; Kwon JG
    Korean J Gastroenterol; 2019 Feb; 73(2):77-83. PubMed ID: 30845383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drugs under development for the treatment of functional dyspepsia and related disorders.
    Tack J; Masuy I; Van Den Houte K; Wauters L; Schol J; Vanuytsel T; Vandenberghe A; Carbone F
    Expert Opin Investig Drugs; 2019 Oct; 28(10):871-889. PubMed ID: 31566013
    [No Abstract]   [Full Text] [Related]  

  • 35. A young man with persistent dyspepsia: the unexpected virtue of proton-pump inhibitors.
    Fraticelli P; Mattioli M; Benfaremo D; Biondi L; Cardinali M; Gabrielli A
    Acta Biomed; 2019 Jan; 89(4):569-572. PubMed ID: 30657126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implications of eosinophilia in the normal duodenal biopsy - an association with allergy and functional dyspepsia.
    Walker MM; Salehian SS; Murray CE; Rajendran A; Hoare JM; Negus R; Powell N; Talley NJ
    Aliment Pharmacol Ther; 2010 Jun; 31(11):1229-36. PubMed ID: 20222916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dyspepsia.
    Quigley EM; Keohane J
    Curr Opin Gastroenterol; 2008 Nov; 24(6):692-7. PubMed ID: 19122517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
    Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
    J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Functional dyspepsia: the past, the present and the Rome III classification].
    Buzás GM
    Orv Hetil; 2007 Aug; 148(33):1573-9. PubMed ID: 17686677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New considerations in the treatment of functional dyspepsia].
    Herszényi L; Juhász M; Tulassay Z
    Orv Hetil; 2004 Apr; 145(14):747-54. PubMed ID: 15131990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.